Skip to main content
. 2020 Oct 26;36(1):34–47. doi: 10.1080/14756366.2020.1835883

Table 2.

HDACs inhibitory selectivity profile of selected hydroxamic acids, SAHA, entinostat and tubastatin A.

Compd. Chemical structure IC50 (µM)a
HDAC1 HDAC3 HDAC6 HDAC8
SN2 graphic file with name IENZ_A_1835883_ILG0011_B.gif 0.698 0.058 0.316 8.206
VS16 graphic file with name IENZ_A_1835883_ILG0012_B.gif 0.593 0.043 0.406 13.680
LD10 graphic file with name IENZ_A_1835883_ILG0013_B.gif 6.043 0.594 0.836 >30
VS13 graphic file with name IENZ_A_1835883_ILG0014_B.gif 0.137 0.040 0.010 9.29
SAHA   0.007 0.0014 0.0014 0.495
Entinostat   1.480b 0.790b >30b >30b
Tuastatin A   2.866 0.766 0.015 2.341

aCompounds were tested in duplicate in a 10-point dose curve with 3-fold serial dilution starting from 30 μM. In the case of SAHA a 15-point dose curve on HDACs 3 and 6 was performed. bSee ref.34.